Long-Term Use of Relacorilant for Cushing Syndrome

"There have been 6 trials involving relacorilant completed or underway since 2018 in cities across 12 different countries. The first of these was a Phase 2 clinical trial sponsored by Corcept Therapeutics. It included 75 patients and concluded in 2018. Since then, 9 more studies have taken place."

"Given that this is a Phase 2 trial, meaning there is only limited data supporting safety but none regarding efficacy, relacorilant was given a score of 2."

"Unfortunately, the information available on clinicaltrials.gov suggests that this particular trial is not recruiting patients at this time. Although 1462 other studies are currently underway."

"Presently, there are six trials for relacorilant underway. Two of these studies are in their third and final phase. Most research concerning relacorilant is conducted in Bucuresti, Oklahoma; however, 215 medical centres across the globe are running trials for this medication."

"Enrollment for this study is currently underway at 37 hospitals, located in cities such as Wilmington, Fall River and Chicago. If you enroll in the trial, try to select a hospital close to minimize travel time and effort."

"Unfortunately, this trial is not presently looking for new patients. The listing was first posted on May 7th, 2018 and updated most recently on October 24th, 2022. However, there are 1456 trials actively recruiting patients with cushing syndrome and 6 studies for relacorilant that are currently seeking participants."